Login / Signup

Macrophages reprogramming improves immunotherapy of IL-33 in peritoneal metastasis of gastric cancer.

Keying CheYuting LuoXueru SongZhe YangHanbing WangTao ShiYue WangXuan WangHongyan WuLixia YuBaorui LiuJia Wei
Published in: EMBO molecular medicine (2024)
Peritoneal metastasis (PM) has a suppressive tumor immune microenvironment (TIME) that limits the effects of immunotherapy. This study aimed to investigate the immunomodulatory effects of intraperitoneal administration of IL-33, a cytokine that is reported to potentiate antitumor immunity and inhibit metastasis. We found survival was significantly prolonged in patients with high IL-33 mRNA expression. In immunocompetent mice, intraperitoneal administration of IL-33 could induce a celiac inflammatory environment, activate immunologic effector cells, and reverse the immunosuppressive tumor microenvironment, which effectively delayed tumor progression and PM of gastric cancer. Mechanistically, IL-33 could induce M2 polarization by activating p38-GATA-binding protein 3 signaling. IL-33 combined with anti-CSF1R or p38 inhibitor to regulate tumor-associated macrophages (TAMs) had a synergistic antitumor effect. Inducing a local inflammatory milieu by IL-33 administration provided a novel approach for treating peritoneal metastasis, which, when combined with TAM reprogramming to reshape TIME, can achieve better treatment efficacy.
Keyphrases
  • air pollution
  • binding protein
  • stem cells
  • particulate matter
  • type diabetes
  • drug delivery
  • heavy metals
  • dendritic cells
  • skeletal muscle
  • risk assessment
  • cell proliferation
  • cell cycle arrest
  • cancer therapy